549 related articles for article (PubMed ID: 27373504)
1. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.
Beatty GL; O'Hara M
Pharmacol Ther; 2016 Oct; 166():30-9. PubMed ID: 27373504
[TBL] [Abstract][Full Text] [Related]
2. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
3. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
[TBL] [Abstract][Full Text] [Related]
4. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
[TBL] [Abstract][Full Text] [Related]
5. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.
Fucà G; Reppel L; Landoni E; Savoldo B; Dotti G
Clin Cancer Res; 2020 Jun; 26(11):2444-2451. PubMed ID: 32015021
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor transduced T cells: Tuning up for the next generation.
Schubert ML; Hoffmann JM; Dreger P; Müller-Tidow C; Schmitt M
Int J Cancer; 2018 May; 142(9):1738-1747. PubMed ID: 29119551
[TBL] [Abstract][Full Text] [Related]
8. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.
Zhu Y; Wang K; Yue L; Zuo D; Sheng J; Lan S; Zhao Z; Dong S; Hu S; Chen X; Feng M
Pharmacol Res; 2024 May; 203():107186. PubMed ID: 38641176
[TBL] [Abstract][Full Text] [Related]
9. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
Bagley SJ; O'Rourke DM
Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.
Morello A; Sadelain M; Adusumilli PS
Cancer Discov; 2016 Feb; 6(2):133-46. PubMed ID: 26503962
[TBL] [Abstract][Full Text] [Related]
11. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
[TBL] [Abstract][Full Text] [Related]
13. Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors.
Mata M; Gottschalk S
Drugs; 2019 Mar; 79(4):401-415. PubMed ID: 30796733
[TBL] [Abstract][Full Text] [Related]
14. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
15. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
Beatty GL; Haas AR; Maus MV; Torigian DA; Soulen MC; Plesa G; Chew A; Zhao Y; Levine BL; Albelda SM; Kalos M; June CH
Cancer Immunol Res; 2014 Feb; 2(2):112-20. PubMed ID: 24579088
[TBL] [Abstract][Full Text] [Related]
16. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
[TBL] [Abstract][Full Text] [Related]
18. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults.
Talleur AC; Fabrizio VA; Aplenc R; Grupp SA; Mackall C; Majzner R; Nguyen R; Rouce R; Moskop A; McNerney KO
Transplant Cell Ther; 2024 Jun; 30(6):565-579. PubMed ID: 38588880
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.
Huang Y; Li D; Qin DY; Gou HF; Wei W; Wang YS; Wei YQ; Wang W
Gene Ther; 2018 Jun; 25(3):192-197. PubMed ID: 28820501
[TBL] [Abstract][Full Text] [Related]
20. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner J; Wickman E; DeRenzo C; Gottschalk S
Mol Ther; 2020 Nov; 28(11):2320-2339. PubMed ID: 32979309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
